Samsara BioCapital

Samsara BioCapital is a Palo Alto-based seed, Series A, and Series B healthcare and life sciences venture capital firm focused on biopharmaceutical companies developing innovative therapies for rare diseases, genetic disorders, and oncology. The firm was founded by Srini Akkaraju and invests with initial checks from $3 million to $15 million. Portfolio companies include Aavantibio, the gene therapy company developing treatments for rare neuromuscular diseases; Disc Medicine, the haematology-focused biopharmaceutical company; Larimar Therapeutics, the clinical-stage company developing treatments for mitochondrial diseases; and Prime Medicine, the gene editing company using Prime Editing. Beyond its original investments, the portfolio includes additional early-stage biopharmaceutical companies.